Potential of Bidara Leaf as Adjunctive Therapy against Breast Cancer Cell Line: A Review

Author:

Audrein Yansen Ifuling1,Indah Budhy Theresia2,Patera Nugraha Alexander3,Joestandari Florentina4,binti Tengku Ahmad Noor Tengku Natasha Eleena5

Affiliation:

1. Graduate Student of Immunology, Post Graduate School, Universitas Airlangga, Surabaya 60115 Indonesia.

2. Department of Oral and Maxillofacial Pathology, Faculty of Dental Medicine, Universitas Airlangga, Surabaya 60115, Indonesia.

3. Department of Orthodontics, Faculty of Dental Medicine, Universitas Airlangga, Surabaya 60115, Indonesia.

4. Faculty of Dentistry, Institute of Health Bhakti Wiyata, Kediri, Indonesia.

5. Membership of Faculty of Dental Surgery, Royal Collage of Surgeon, Edinburgh University, United Kingdom.

Abstract

Background: Breast cancer or Carcinoma mammae is a malignancy that damage the gland ducts, and breast supporting tissues. Breast cancer is ranked first as a malignancy that often occurs in the world. The majority of women with breast cancer will have many surgeries. Chemotherapy is frequently used in conjunction with surgery. However, the side effects of chemotherapy drugs can damage healthy cells. Bidara leaf are one of the most promising sources of bioactive compounds for the pharmaceutical field in the treatment of breast cancer. Aims: This review article aims to describe the several types of Bidara leaf that contain compounds and anticancer activity that have potential as alternative treatments for breast cancer through narrative review. Review:This review article discusses several types of Bidara leaf and their anticancer activity. Conclusion: From the results of a journal review, it was found that several types of Bidara leaf with breast anticancer activity were Ziziphus spina christi, Zizyphus mauritiana, Ziziphus nummularia, with various activities such as cytotoxicity, antiproliferative, proapoptotic, and proinflammatory on the MCF-7 breast cancer cell line.

Publisher

A and V Publications

Reference24 articles.

1. Kristian RA, Sandhika W, Heriyawati. Expression Level of HSP70 and COX-2 in Breast Cancer Proliferation in Dr. Soetomo General Hospital, Surabaya, Indonesia. Research Journal of Pharmacy and Technology. 2022; 15(4):1636-0.

2. Mohammed AJ. Tumor Suppressor Gene Mutations in Iraqi Women with Breast Cancer and Their Relatives. Research J. Pharm. and Tech. 2018; 11(10): 4467-4472.

3. Moselmani F, Al-Saleh J.Relation between Serum cyclo oxygenase-2 values and Tumor characteristics in breast cancer patients. Research J. Pharm. and Tech. 2020; 13(9):4320-4322.

4. Vania L, Widyananda MH, Kharisma VD, Ansori ANM, Naw SW, Maksimiuk N et al. Anticancer Activity Prediction Of Garcinia Mangostana L. Vagainst Her2-Positive Breast Cancer Through Inhibiting Egfr, Her2 And Igf1r Protein: A Bioinformatics Study. Biochemical and Cellular Archives. 2021 Oct;21(2):3313-3321.

5. Widyananda MH, Ansori ANM, Kharisma VD, Rizky WC, Dings TGA, Rebezov M et al. Investigating The Potential Of Curcumin, Demethoxycurcumin And Bisdemethoxycurcumin As Wild-Type And Mutant Her2 Inhibitors Against Various Cancer Types Using Bioinformatics Analysis. Biochemical and Cellular Archives. 2021; 21(2): 3335-3343.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3